Congo Ebola outbreak reaches 1,502 cases as death toll rises to 473

The Democratic Republic of the Congo (DRC) has recorded 1,502 confirmed cases of Bundibugyo virus disease, including 473 deaths, as the country confronts the largest documented outbreak caused by this form of Ebola.

Government data released on July 3, 2026, showed that confirmed infections had spread across Ituri, North Kivu and South Kivu provinces in eastern Democratic Republic of the Congo. The latest figures mean that nearly one in three confirmed patients has died, while continuing insecurity and population movement are making surveillance, treatment and contact tracing considerably more difficult.

The worsening outbreak comes as the World Health Organization begins enrolling patients in the first major clinical trial designed to identify an effective treatment specifically for Bundibugyo virus disease. Unlike the better-known Zaire Ebola virus, the Bundibugyo virus currently has no licensed vaccine and no approved virus-specific treatment.

The World Health Organization has classified the outbreak in the Democratic Republic of the Congo and neighbouring Uganda as a Public Health Emergency of International Concern. The organisation has not classified it as a pandemic emergency, but has warned that cross-border movement, weak health infrastructure and conflict could allow the outbreak to spread further if response operations fail to keep pace.

How quickly has the Bundibugyo Ebola outbreak expanded across eastern Congo?

The outbreak was officially declared by the Democratic Republic of the Congo on May 15, 2026, after health authorities investigated clusters of severe illness and unexplained deaths in the Mongbwalu, Rwampara and Bunia health zones of Ituri Province.

The first currently recognised suspected patient was a healthcare worker who developed fever, vomiting, bleeding and severe weakness on April 24 before dying at a medical centre in Bunia. Four healthcare workers died within a short period, raising early concerns that transmission was occurring inside medical facilities that lacked adequate infection-control protections.

By May 16, only eight laboratory-confirmed cases had been reported, although authorities had already identified 246 suspected cases and 80 suspected deaths. The World Health Organization warned at the time that limited testing and incomplete epidemiological links meant the true scale was probably substantially larger.

The official confirmed total then rose rapidly as laboratories tested backlogged samples and surveillance expanded into additional areas. The Democratic Republic of the Congo had reported 676 confirmed cases and 136 deaths by June 10, followed by 896 cases and 232 deaths by June 17. By July 2, the total had reached 1,406 confirmed cases and 438 deaths, before increasing to 1,502 cases and 473 deaths in the July 3 government update.

The rise between reporting dates should not automatically be interpreted as showing that every additional patient became infected during the preceding day. Expanded laboratory capacity can convert previously suspected cases into confirmed cases, while investigations can retrospectively classify deaths that occurred before the outbreak was formally recognised.

However, the continuing geographical expansion into Ituri, North Kivu and South Kivu shows that the outbreak has moved beyond its original cluster. Each additional health zone creates new requirements for treatment centres, protective equipment, laboratories, trained personnel and community outreach.

Why is Bundibugyo virus disease harder to contain than more familiar Ebola outbreaks?

Bundibugyo virus is one of the Ebola virus species known to cause large and potentially fatal outbreaks in humans. It spreads through direct contact with the blood or other bodily fluids of an infected person, including people who have died, and through objects or surfaces contaminated by those fluids.

Symptoms can begin with fever, fatigue, muscle pain, headache and sore throat. Patients may subsequently develop vomiting, diarrhoea, rash, impaired kidney or liver function and, in some cases, internal or external bleeding. Early symptoms can resemble malaria, typhoid or other common illnesses, increasing the risk that an infected patient will initially enter an ordinary clinic without isolation precautions.

The principal medical disadvantage is that tools developed for Zaire Ebola do not automatically protect patients against Bundibugyo virus. Licensed vaccines used during previous outbreaks target Zaire ebolavirus and are not approved as a dependable preventive measure against the Bundibugyo species.

Two monoclonal antibody treatments approved for Zaire Ebola are similarly not established treatments for Bundibugyo virus disease. Patients therefore depend heavily on early identification and intensive supportive care, including fluids, electrolyte replacement, oxygen, pain management and treatment for falling blood pressure or organ complications.

Past Bundibugyo outbreaks produced reported fatality rates of approximately 30% to 50%. Survival improves when patients reach specialised treatment units early, but delayed diagnosis can allow dehydration, shock and organ damage to become more difficult to reverse.

The absence of an established vaccine also limits ring vaccination, a strategy that has helped contain Zaire Ebola by immunising contacts and contacts of contacts around each detected case. The Bundibugyo response must consequently rely more heavily on rapid testing, isolation, contact follow-up, safe burials and community cooperation.

Why are conflict and population movement making the Congo Ebola response more dangerous?

Eastern Democratic Republic of the Congo is affected by armed conflict, displacement, informal mining, cross-border trade and repeated movements between rural communities and densely populated towns.

Insecurity can prevent health teams from reaching villages, following exposed contacts and transporting sick patients to specialised treatment centres. Armed violence can also force entire communities to move suddenly, separating health workers from people who were under observation.

The initial response illustrated the problem. The World Health Organization said only 21% of listed contacts in Ituri were being successfully followed as of May 21, partly because insecurity and movement restrictions obstructed surveillance. More than 1,600 contacts had already been identified at that stage.

Mining and commercial activity create additional routes for transmission. Ituri and the Kivu provinces contain highly mobile populations whose work may require travel between mines, markets, border crossings and urban centres. An infected person can travel before severe symptoms appear, making it difficult to identify everyone exposed during the journey.

The region also contains many informal or lightly regulated health facilities. Patients may seek treatment from several providers before entering an Ebola treatment centre, potentially exposing relatives, traditional healers and medical workers who lack protective equipment.

The World Health Organization identified these conditions when declaring the emergency, warning that conflict, humanitarian need, urban or semi-urban transmission and weak infection controls could reproduce some of the difficulties experienced during the major North Kivu and Ituri Ebola epidemic of 2018 and 2019.

Containing the outbreak therefore requires more than medical supplies. Response teams need physical access, negotiated security, community trust and reliable communication across locations where state authority is limited or contested.

Could the new PARTNERS treatment trial finally produce an effective therapy?

Patient enrolment began on July 2 in the PARTNERS clinical trial, formally known as the Platform Adaptive Randomised Trial for New and Repurposed Filovirus Treatments.

The trial will evaluate two potential therapies, MBP134, a monoclonal antibody treatment, and the antiviral remdesivir. Researchers will test the medicines separately and in combination to determine whether they improve survival among patients with confirmed Bundibugyo virus disease.

The randomised controlled trial is open to confirmed patients of any age. Participants will continue receiving supportive care, and an independent data and safety monitoring board will regularly review the results for evidence of benefit or harm.

The platform structure allows researchers to add other promising treatments without creating an entirely new trial for every candidate. This could accelerate the evaluation of new medicines during the current outbreak and future emergencies involving Ebola or Marburg viruses.

The World Health Organization is sponsoring the research in coordination with the Democratic Republic of the Congo’s Institut National de Recherche Biomédicale, the University of Oxford, Belgium’s Institute of Tropical Medicine, the Africa Centres for Disease Control and Prevention and humanitarian medical organisations.

More than 200 patients had recovered before enrolment began, showing that supportive treatment can save lives even without a proven antiviral therapy. An effective medicine could nevertheless reduce mortality, shorten illness and encourage patients to seek treatment earlier if communities believe specialised centres offer a better chance of survival.

The trial will not produce immediate protection for every patient. Researchers need sufficient enrolment and follow-up to determine whether observed improvements are caused by the medicine rather than differences in disease severity, timing of care or other factors.

How could the first WHO-listed diagnostic test change the outbreak response?

The World Health Organization added the first molecular test for Bundibugyo virus to its Emergency Use Listing on July 2, providing governments and international procurement agencies with a quality-assessed tool for detecting the virus’s genetic material in blood.

Emergency Use Listing does not mean every affected clinic immediately receives the test. It gives purchasers confidence that the product meets minimum requirements for performance, quality and safety, allowing procurement and distribution to proceed more rapidly during an emergency.

Testing capacity has already expanded significantly. The initial laboratory network relied largely on the Institut National de Recherche Biomédicale facilities in Kinshasa and Goma, with a combined estimated capacity of 200 to 400 tests a day.

By July 2, the network had expanded to 10 laboratories across affected provinces, with reported capacity exceeding 2,000 tests daily. Additional products, including laboratory tests, near-patient molecular systems and antigen rapid tests, are being assessed.

Faster diagnosis can reduce the period during which a sick person remains in an ordinary household or clinic. It also allows health authorities to begin contact tracing sooner, transfer confirmed patients safely and release people who test negative from unnecessary isolation.

Laboratory expansion partly explains the rapid rise in confirmed numbers. A higher total can initially appear to represent worsening control, but identifying previously undetected cases is necessary before transmission chains can be interrupted.

The remaining challenge is transporting samples from remote and insecure communities. A high-capacity laboratory provides limited value when roads are blocked, couriers cannot travel safely or results take several days to reach clinicians.

How serious is the risk that the Ebola outbreak will spread beyond Congo and Uganda?

International spread has already occurred. Uganda confirmed cases in May among people who had travelled from the Democratic Republic of the Congo, and later identified secondary transmission among contacts and healthcare workers.

The World Health Organization declared a Public Health Emergency of International Concern because the outbreak posed risks to other countries and required coordinated surveillance, laboratory readiness and clinical preparation. It explicitly stated that the situation did not meet the definition of a pandemic emergency.

Countries bordering the Democratic Republic of the Congo face the highest immediate risk because people routinely cross land borders for work, trade, healthcare and family reasons. Uganda, South Sudan, Rwanda, Burundi and the Republic of the Congo have strengthened surveillance and preparedness measures.

The World Health Organization has not recommended blanket international travel restrictions. Broad border closures can push travellers toward unofficial crossings, damage local livelihoods and make health monitoring harder by driving movement outside regulated systems.

The more effective approach is targeted health information, rapid investigation of sick travellers, prepared isolation facilities and coordination between neighbouring countries. Governments also need procedures for safely transferring samples and referring patients without exposing transport workers.

A small number of imported cases does not necessarily lead to sustained national transmission when health systems detect and isolate patients quickly. The larger danger is an unidentified patient receiving treatment in several facilities before Ebola is suspected.

Can community trust prevent funerals and clinics from becoming transmission centres?

Public cooperation is essential because Ebola control measures enter deeply personal areas of family and community life.

Health teams must ask relatives not to touch or wash the body of someone who has died, even though these actions may form an important part of mourning and burial traditions. Bodies can contain high concentrations of virus, making funerals a major transmission risk when protective procedures are absent.

Families may also fear that relatives taken to treatment centres will never return or that they will be buried without dignity. Rumours can cause people to hide patients, avoid testing or attack response workers.

The World Health Organization has urged authorities to involve religious leaders, traditional leaders and healers in explaining why early treatment, isolation and safe burial procedures are necessary. Community representatives can help ensure that medical precautions are applied respectfully rather than experienced as coercion.

Trust also depends on ordinary healthcare continuing during the outbreak. A clinic focused entirely on Ebola may fail patients with malaria, childbirth complications, injuries or chronic conditions, increasing resentment and preventable deaths unrelated to the virus.

Health workers require protective equipment, training, salaries and hazard compensation. When clinicians become infected, communities lose essential personnel and may begin viewing healthcare facilities themselves as dangerous.

The outbreak cannot be ended only by laboratories and experimental medicines. Each transmission chain must ultimately be discovered through people reporting illness, sharing contact information and accepting measures that temporarily disrupt daily and religious practices.

What are the key takeaways from Congo’s rapidly expanding Bundibugyo Ebola outbreak?

• The Democratic Republic of the Congo reported 1,502 laboratory-confirmed Bundibugyo virus disease cases and 473 deaths by July 3, 2026, across the eastern provinces of Ituri, North Kivu and South Kivu.
• The outbreak was officially declared on May 15 after clusters of unexplained illness and healthcare-worker deaths were investigated in Mongbwalu, Rwampara and Bunia, although evidence indicates transmission began during April.
• Bundibugyo virus disease currently has no licensed virus-specific vaccine or approved treatment, making early diagnosis, intensive supportive care, isolation, contact tracing and safe burial practices the main established response tools.
• The World Health Organization has classified the outbreak affecting the Democratic Republic of the Congo and Uganda as a Public Health Emergency of International Concern, but not as a pandemic emergency.
• The PARTNERS clinical trial began enrolling patients on July 2 to evaluate the monoclonal antibody MBP134, remdesivir and a combination of both therapies as possible treatments capable of reducing mortality.
• The World Health Organization also listed the first quality-assessed molecular diagnostic for Bundibugyo virus, while testing capacity expanded from a few hundred samples daily to more than 2,000 across 10 laboratories.
• Armed conflict, displaced populations, mining activity, informal healthcare facilities and cross-border trade are obstructing contact tracing and increasing the risk that infected people will travel before being diagnosed.
• Neighbouring countries remain vulnerable to imported infections, but international health authorities advise surveillance, laboratory preparation and regulated cross-border coordination rather than blanket travel bans that could drive movement through unofficial routes.